Background Benign prostatic hyperplasia is reported to affect 6% of population globally. BPH is a pathologic process that describes proliferative events of prostate gland cells. The development of an alternative medications against BPH based on natural components have become a priority in human and animal therapy. Present study was aimed to evaluate the role of Paeoniflorin-a terpene glycoside against testosterone induced benign prostatic hyperplasia of Wistar rats. Methods The animals were randomly assigned in to 6 groups, each group containing 6 animals: Group I: the vehicle control group (vehicle control group), Group 2: the BPH model group (BPH), Group 3: the BPH-5 mg/kg paeoniflorin group (paeoniflorin group),Group 4: the BPH-10 mg/kg paeniflorin group (paeniflorin group), Group 5: the BPH-15 mg/kg paeniflorin group (paeniflorin group) and Group 6: BPH-1 mg/kg finasteride group. Result Paeoniflorin significantly reduced the oxidative damage by increasing the activity of anti-oxidative armory and reducing the oxidative marker. A protective role of paeoniflorin against inflammation was established in blocking of NF-κB activation along with the lowering of inflammatory markers. It also reduced hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), transforming growth factor β (TGF β1) and confirms its role as anti-angiogenic phytochemical. It increased the epithelial marker E-Cadherin, reduced the activity of mesenchymal marker vimentin and reduced the activity of androgen receptor. Anti-BPH role of paeoniflorin is established in this study by blocking AR–androgen binding. Conclusion our study suggests the ameliorating effect of paeoniflorin against BPH of Wistar rats possibly by interfering NF-κB/AR signaling pathway.
Rashid et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: